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Available online 1 March 2016Background: Anemia is found to be an independent risk factor of morbidity, mortality and hospitalization among
patients with heart failure. The prevalence, as the potential treatment options of anemia in HF has received
increasing clinical interest and epidemiological studies have indicated a variation in the prevalence of anemia
in patients with HF.
Method: Electronic search took place in the databases: Pubmed, Cochrane and CINAHL to locate studies in English that
investigated the effect of anemia in patientswithHF. The overall pooled effect (relative risk, RR) of anemia as comorbid
factor compared with HF patients without anemia was estimated by using a random effects analysis (95% conﬁdence
interval (CI) for the outcomes of HF— related mortality rate, re-hospitalization and physical condition.
Results: Twenty-six studieswere selected. In the overall RRofmortality, re-hospitalization and extendedhospitalization
was 1.70, 95% CI (1.47–1.98), p b 0.00001, for readmission rate 1.57, 95% CI (1.17, 2.10), p = 0.003 and 1.25, 95% CI
(0.59–1.90), p=0.0002 respectively in behalf of heart failure patientswithout anemia. Likewise, patientswith anemia
tend tohaveworse functionality according toNYHAclassiﬁcation 1.23, 95% (CI 0.99–1.52), p=0.06. Ameta-regression
analysis conducted in an effort to explain the heterogeneity of mortality.
Conclusion: Themeta-analysis gives an outline proﬁle of patientswith the co-morbidityHF and anemia in terms of clin-
ical outcomes. The results point out worse prognosis in HF patients with anemia. Nevertheless, the available data did
not allow the extraction of a conclusion in which exact Hb levels anemia becomes a negative predictor of prognosis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Heart failure is a chronic clinical syndrome that is associated with
signiﬁcant mortality, morbidity, and healthcare costs. Frequently,
patients with HF experience hospitalizations and even though there
are new therapies, the mortality rate of heart failure (HF) patients
is still high [1–3]. Furthermore, HF estimates 5% and 2% of all hospital
admissions and global health spending respectively [4–6].
Despite the new therapies, prognosis in HF remains poor. More
speciﬁcally, the mortality rate ranges from 30 to 40% in the ﬁrst year
and 60–70% in the ﬁrst ﬁve years. Also, this condition affects the quality
of life of the patients [4,6–7]. This poor prognosis worsens even more
when co-morbidities such as anemia, diabetes mellitus (DM) or chronicfailure; Hb, Hemoglobin; LOS,
tion; AF, atrial ﬁbrillation; GFR,
DBP, diastolic blood pressure;
yriakou).
eliability and freedom from bias
. This is an open access article underkidney failure co-exist [8–10], anemia is a co-morbidity of great interest.
Over the last decade, the prevalence, as the potential treatment options
of anemia in HF have received increasing clinical interest and epidemi-
ological studies have indicated a wide variation in the prevalence of
anemia in patients with chronic HF [8,11–13]. More speciﬁcally, the
prevalence of anemia in HF patients varies in published studies from
4 to 55%, due to heterogeneous patient populations and the lack of
speciﬁc deﬁnition [12,14–17].
As mentioned above, varied deﬁnitions of anemia have been used
including hematocrit b30–37%, hemoglobin b12 mg/dL and the deﬁni-
tion from the World Health organization (WHO). According to WHO,
anemia is deﬁned as hemoglobin less than 12 g/dl for women and less
than 13 g/dl for men [18–21].
In addition, several projects have demonstrated that anemia with
the presence of HFwas a predictor ofmorbidity, mortality and hospital-
ization and also a negative impact on patient's quality of life.
1.1. Aim
The goal of the present systematic review and meta-analysis is to
investigate the prognosis of anemia in patients with heart failure.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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To investigate the prognosis of the co-morbidity of anemia and heart
failure, examining the following clinical outcomes:
• the mortality rate between patient's with and without anemia;
• the re-hospitalization frequency among patients with and without
anemia;
• if there is a difference regarding the length of hospital stay among
patients with and without anemia; and
• the association between the co-morbidity and the functionality of the
patients according to NYHA classiﬁcation.
2. Methods
2.1. Design
The present study is a systematic review and meta-analysis of
studies assessing the relation of anemia and HF on outcomes of mortal-
ity frequency of hospitalization, length of stay in the hospital, and
mortality. Using a meta-regression analysis, we want to estimate the
heterogeneity of the studies included in the meta-analysis. In order to
select the studies that would be included in the meta-analysis, we set
some criteria as is referenced below. To assess the studies and to con-
duct the current meta-analysis, we used the checklist of Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
2.2. Search strategy
The search of the literaturewas conducted fromMay 2014 until June
2014. The articles research took place in the electronic databases:
Pubmed, Cochrane Library and CINAHL. To conduct the search, we
used the combination of thewords: “heart failure”,” anemia”, “and read-
mission “and”NYHA class”. A combination of all words took place using
the word AND.
In order to select the articles we set the following criteria: The
articles should be published in the English language in the last decade
(2004–2014) and should have examined clinical outcomes of the co-
morbidity HF-anemia. The aim of the study, speciﬁcally, should be
one or more of the following clinical outcomes: frequency of re-
admissions, mortality and/or length of hospital stay. The exclusion
criteria where the following: articles that were in another language,
except English and studies that have been published before 2004. Fur-
thermore, we excluded studies that were examining the effectiveness
of anemia treatments. Last but not least, we excluded articles that
have been referred generally for cardiovascular problems and not
speciﬁcally for HF. It is noticeable to highlight that we did not exclude
articles that were referred in other co-morbidities that usually co-exist
with HF, as HF is a complicated syndrome with a lot of co-morbidities.
Although, we did include these articles in the meta-analysis only if
the results of HF and anemia were separated from the rest of the
co-morbidities.
2.3. Evaluation and selection of studies
Overall, from the research in the databases: PubMed, Cochrane
library and CINAHL 3831 studies have come to light. After reading the
studies title, 3580 were excluded and therefore 251 studies remained
for further investigation. Eighteen studies were excluded, because
they were published in other languages except English.
Furthermore, based on the inclusion and exclusion criteria studies,
excluded after reading the abstract as they investigated: 1) effectiveness
of therapy, 2) other co-morbidities of HF and the results were not sepa-
rated for anemia, 3) how changes in Hb level can inﬂuence the rate of
morbidity or mortality 4) they compare different subgroups of patients
with heart failure and anemia between them. Also, studies excluded inthis stage; 1) were not speciﬁc for HF (they include other cardiac
complications), they investigated differences for patients with HF and
anemia, comparing in-patients and out-patients and ﬁnally few studies
did not examine any of the clinical outcomes of our interest.
Moreover, 150 studieswere reviews, systematic reviews or Scientiﬁc
Integrity Reviews, two of them meta-analyses and the following two
reports were not found as a full text.
Lastly, six studies were found to be the same studies from different
databases or different combination of words and two of the studies
were excluded after reading the whole report document. These studies
were excluded because their data was in a form that we could not use
them.
After the above process, twenty-six studies were found to meet the
inclusion criteria and therefore, a critical appraisal applied for the com-
pleteness of information, design and implementation. Various amounts
of studies were more or less methodologically good. The main features
of each study are summarized in the Table 1 and the process undertaken
is indicated in Fig. 1.
2.4. Statistical analyses
In order to conductmeta-analysis of the data that have been extract-
ed from each study we used the software program Review Manger 5.3
of Cochrane Library. The primary measures of the meta-analysis were
the following clinical outcomes:mortality, readmission, length of hospi-
tal stay and the correlationwith theNYHA functional class if any. Firstly,
we estimate the heterogeneity of the studies. According to the results,
we chose to perform the random effect models by the DerSimonian
and Laird. In addition this model takes into account both the between
and within studies variability.
In each comparison we calculated the quantitative heterogeneity
visually using Q (x2) and I2 statistics. We also calculated the 95% CI in
each comparison. The sameprocess has been followed for the secondary
outcomes of the meta-analysis.
Funnel plot was performed to assess the publication bias. The funnel
plot was not skewed or asymmetrical, which represent absent of publi-
cation bias. When the funnel plot has these two characteristics, it is due
to publication bias; exclusion of small studies or exclusion of studies
with “negative” results.
3. Results
The current search found a total of 26 studies that met the inclusion
criteria for themeta-analysis. Thirteen of these studieswere prospective
correlation studies [3,10,22–32] ,nine were retrospective correlation
[6,16,18,33–37,40] and twoof themwere descriptive correlation studies
[41–42]. Also in one study the authors collected the data retrospectively
and prospectively (two studies in one) [43]. In regards to the country
that each research was conducted in, two of them were in Brazil, two
Table 1
Main features of the included studies.
Author Year n Mean
age
Study outcomes Follow-up
period
Study quality based on the
Ottawa–Newcastle Scale
Anemia deﬁnition
Anand et al 2004 912 Mortality and readmission 12,7 months 8 Hb b 12 g/dl
Anand et al. 2005 5002 Mortality 2 years 7 WHO
Bermejo et al 2007 460 Mortality, readmission 16,8 months 9 WHO
Cardoso et al 2010 99 65 Mortality, LOS 4 months 7 Hb b 12 g/dl
Charlot et al. 2010 1518 Mortyality 13 to 15 years 8 WHO
Dunlay et al. (prospective) 2009 677 Mortality 21 months 8 WHO
Dunlay et al. (retrospective) 2009 1063 Mortality 5,3 years 8 WHO
Ellabasi et al. 2006 437 64,6 Mortality, readmission ≈1,5 years 9 WHO
Ferreira et al 2008 296 50,6 Mortality 1 year 7 WHO
Formiga et al. 2005 103 78,5 Mortality, readmission 1 year 9 WHO
Hamaguchi et al. 2009 1960 Mortality, readmission 2 to 3 years 9 4 different groups as they estimate
Lupon et al. 2005 337 65,4 Mortality, readmission 1 year 9 Hb b 12 g/dl
Luthi et al. 2006 955 75,4 Mortality, readmission, LOS 30 days 8 4 different groups as they estimate
Nathavitharana et al 2011 1491 Mortality, readmission, LOS 16 months 8 WHO
Oster et al. 2012 2332 Mortality 33,6 months 8 WHO
Rovellini et al. 2012 200 Mortality In-hospital 7 WHO
Saraiva et al 2011 391 59,6 Mortality, readmission, LOS 3,2 years 8 WHO
Shamagian et al. 2006 210 73,2 Mortality 1,5 years 9 WHO
Steward et al. 2011 959 Mortality, readmission 1 year 8 Hb b 12 g/dl
Tada et al 2007 357 67,7 Mortality 3,6 years 7 WHO
Tarantini et al. 2011 2318 72 Mortality 2 years 8 Hb b 12 g/dl
Tehrani et al. 2009 294 78 Mortality 5 years 9 WHO
Teng et al 2009 1000 76,3 Mortality, LOS 5 years 8 WHO
Torrijos et al. 2006 242 72 Mortality, readmission 23,5 months 9 Hb b 12 g/dl
Von Haehling et al 2009 627 73,3 Mortality, LOS 61 months 9 WHO
Waldum et al 2012 4144 70,2 Mortality 28 months 9 WHO
Young et al 2008 48,612 73,2 Mortality, readmission, LOS 60 to 90 days 7 Hb b 10,7 g/dl
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in Australia. The most of the studies and more speciﬁcally ﬁve of them
conducted in Spain. In each one of the following countries, one of the
studies took place: Canada, UK, Portugal, Slovenia, Norway, Denmark
Switzerland and Israel. The remainder two studies were conducted in
more than one country. Speciﬁcally, one of the studies was conducted
in sixteen countries and for the other study we do not have more
data, only that is a multicenter study.
From the twenty-six included studies, ﬁfteen were single center
[6,10,22–24,26–28,34–36,39,42–43] and the rest eleven multicenter
studies [16,18,25,29–33,37,40–41]. Speciﬁcally, the study of Luthi et al.
took place in two hospitals and the study of Teng et al. in three hospitals.
The studies of Steward et al. [30],Waldumet al. [31], Oster et al. [32] and
Charlot et al. [37] took place in seven, ten, twenty-ﬁve and thirty-four
hospitals respectively. In addition, one study took place in 164 hospitals,
another study in 206 hospitals and another study from Young et al.
in 259 hospitals. Last but not least, one study was conducted in 302
medical centers. The sample size of the studies ranged from 86 to
7922 patients.
As for the categorization of the patients, 20 of the studies split the
patients in two categories: patients with anemia and patients without
anemia [3,6,10,22–24,26,28,30–31,34–36,39–43]. The remainder seven
studies separated the patients according to their hemoglobin level and
therefore the severity of the anemia [16,18,25,27,29,32–33,37].
3.1. Methodological quality
In order to assess the methodological quality of the studies the
checklist of Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and the Ottawa–Newcastle Scale were used.
The latter is a scale recommended to assess methodological quality in
observational studies [38]. Three general domains: “selection,” “compa-
rability,” and “outcomes” are what the scale is examining in terms of
quality indicators. The former and the latter have subgroups, in contrast
with the domain comparability. Using a star system, the scale becomes
visually easy to examine each domain. Each variable in the domains
selection and outcomes, could be awarded with one star and thedomain comparability with two stars. The maximum score for a study
is nine stars. Table 2 indicates the assessment of each study included
in the meta-analysis.
The studies could be characterized as of goodmethodology since ten
of themmarked with nine stars, eleven with eight and six of themwith
seven stars. It is worth mentioning that we established one-year follow
up as adequate time.
3.2. Heterogeneity
From the factors included in the meta-analysis we found different
levels of heterogeneity. For the primary outcomes we found high het-
erogeneity except of the outcome length of hospital stay, which may
relay in the fact that data were collected from only four studies. More
speciﬁcally, for the outcomes mortality (x2 = 81.11, I2 = 80%,
p b 0.00001) and readmission rate (x2 = 15.00, I2 = 73%, p b 0.003)
we observe high heterogeneity. Statistically signiﬁcant heterogeneity
had also been observed for the NYHA functional classes I &II (x2 =
6.39, I2 = 53%, p b 0.005) and substantially higher for the classes III
&IV (x2 = 443, I2 = 98%, p = 0.06).
The heterogeneity among the studies and therefore of the meta-
analysis test can easily be explained with two reasons. There are differ-
ent deﬁnitions of anemia used by the authors and also the fact that
patients' population differs in characteristics. Another important feature
is the period of follow up.
3.3. Clinical outcomes
Using the software program ReviewManger 5.3 of Cochrane Library
we concluded to the following results:
3.3.1. Main results
Sixteen of the twenty-six studies examined the variable mortality
for HF-patients with and without anemia. In some studies the outcome
ofmortality was considered a primary outcome combinedwith another
outcome (for instance all cause death or morbidity). The results from
those studies were not included in the meta-analysis. They have been
Fig. 1. Selection of the studies.
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separated.
The variable readmission had been examined in only ﬁve studies.
Likewise with the previous outcome of mortality, most of the studies
deemed a primary outcome combined with another outcome. In this
case most of the studies did not present the results only for the variable
re-admission for HF. Four of the studies had also inspected the outcome
length of hospital stay (LOS). In most of these studies this outcomewas
deemedwith the variable re-admission. The outcome LOSwas indicated
separately only in ﬁve studies.
The last variable was the functionality according to NYHA classiﬁca-
tion (NYHA class III and IV). Nine of the included studies assessed this
outcome. In some studies the NYHA class III was merged with the
NYHA class IV.
The pooled relative risk of mortality at maximal available follow-up
time among patients with anemia was higher than of those withoutanemia (RR 1.70, 95% CI 1.47–1.98). Likewise, readmission rate was
higher in patients with anemia (RR1.57, 95% CI 1.17, 2.10) and they
had more extended hospitalization (MD 1.25, 95% CI 0.59–1.90). Also
patients with anemia tend to have worse functionality according to
NYHA classiﬁcation (NYHA class III and IV RR 1.23, 95% CI 0.99–1.52).
The overall relative risk with their 95% CI and weights are indicated in
the Figs. 2–5. (See Figs. 6– 8.)
3.3.2. Outline proﬁle of HF patents with anemia
Firstly we analyzed the demographic data of the patients and
it seems that patients with anemia tend to be older (MD 3.40, 95% CI
2.33–4.47) and it seems to be slightly higher for the female sex (RR
0.97, 95% CI 0.85–1.11).
Furthermore, illnesses such as hypertension, diabetes, COPD and CRF
that usually co-exist in patients with HF have been presented more
often in patientswith anemia.More speciﬁcally,we found amore positive
Table 2
Methodologically quality of the included studies based on the Ottawa–Newcastle Scale.
Author Selection Combarability Outcome Score
Representativeness
of exposed cohort
Selection of non
exposed cohort
Ascertainment
of Exposure
Outcome of
interest absent
at start of study
Comparability of
Cohorts on the Basis of
the Design or Analysis
Assessment
of Outcome
Length of
follow-up
Adequacy
of follow-up
Anand et al. 2004 * * * * * * * * 8
Anand et al. 2005 * NA * * ** * * NA 7
Bermejo et al. 2007 * * * * ** * * * 9
Cardoso et al. 2010 * * * * ** * NA NA 7
Charlot et al. 2010 * * * * ** * * NA 8
Dunlay et al. 2009
(prospective)
* * * * ** * * NA 8
Dunlay et al. 2009
(retrospective)
* * * * ** * * NA 8
Ellabasi et al. 2006 * * * * ** * * * 9
Ferreira et al. 2008 * * NA * * * * NA 7
Formiga et al. 2005 * * * * ** * * * 9
Hamaguchi et al. 2009 * * * * ** * * * 9
Luthi et al. 2006 * * * * ** * NA * 8
Lupon et al. 2005 * * * * ** * * * 9
Nathavitharanaet al 2011 NA * * * ** * * * 8
Oster et al. 2012 * * * * ** * * NA 8
Rovellini et al. 2012 * * * * * * NA NA 7
Saraiva et al. 2011 * * * * * * * * 8
Shamagian et al. 2006 * * * * ** * * * 9
Steward et al. 2011 * * * * * * * * 8
Tada et al. 2007 * * * * * * * NA 7
Tarantini et al. 2011 * * * * ** * * NA 8
Tehrani et al. 2009 * * * * ** * * * 9
Teng et al. 2009 * * * * ** * * NA 8
Torrijos et al. 2006 * * * * ** * * * 9
Von Haehling et al. 2009 * * * * ** * * * 9
Waldum et al. 2012 * * * * ** * * * 9
Young et al. 2008 * * * * * * NA * 7
* the most important confounders have been adjusted; ** any other adjustments were made; NA Not applicable.
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(RR 2.27 95% CI 2.05–2.51) compared with the illnesses COPD (RR 0.99
95% CI 0.90–1.08) and hypertension (RR 0.92 95% 0.74–1.15).
As for the hemodynamic data both systolic and diastolic blood pres-
sure was signiﬁcantly lower in patients with anemia. (RR 4.39, 95% CI
2.38–6.4)and (RR 5.67 95% CI 4.15–7.19) respectively. In contrast, forFig. 2.Meta-analysis and forest plot comparing patienlaboratory parameters we ﬁgured out a signiﬁcantly lower hemoglobin
level (MD 2.98 95% CI 2.72–3.24) in patients with anemia as
was predicted and slightly higher levels of creatinine (MD 0.35, 95% CI
0.09–0.61). High levels of creatinine in the blood indicates renal failure.
Moreover, we examine if an AF episode is more possible to occur in
patients with heart failure who also have anemia. According to thets with and without anemia. Outcome: mortality.
Fig. 3.Meta-analysis and forest plot comparing patients with and without anemia. Outcome: readmission.
Fig. 4.Meta-analysis and forest plot comparing patients with and without anemia. Outcome: length of hospital stay.
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situations (RR 0.97 95% CI 0.81–1.17). We examined also two possible
etiologies of HF and we tried to investigate if there is any correlation
with anemia. The ischemic and vascular etiology had been examined
and we found that both seem to have the same RR of 1.23 and 1.27
favoring patients with anemia. Last but not least we tried to examine
if smoking is a risk factor that correlates with the co-morbidity under
investigation. The results indicate no signiﬁcant correlation with any
of the groups (RR 0.81 95% CI 0.63–1.03).Fig. 5.Meta-analysis and forest plot comparing patients with aUsing the data from the studies where the patients had been split
into categories instead of just two groups (anemic and non-anemic),
we have done another test for the clinical outcome mortality. From
this test we extracted the same results as from the previous test. Addi-
tionally, could strengthen the conclusion; themore severe is the anemia
the higher is the mortality rate. More speciﬁcally the RR for mild,
moderate and severe anemia is 1.26 (95% CI 1.05–1.50), 1.49 (95%
CI1.06–2.10) and 1.92 (95% CI 1.26–2.92) respectively. Table 3 indicates
the results from the meta-analysis.nd without anemia. Outcome: functionality classiﬁcation.
Fig. 6.Meta-analysis and forest plot comparing patients with and without anemia based on WHO deﬁnition. Outcome: mortality.
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We performed a sensitivity analysis for the variable mortality, exclud-
ing all the studies that did not determine anemia by WHO deﬁnition. InFig. 7. Sensitivity analysis for
Fig. 8.Meta-analysis and forest plod adjusting anorder to perform this analysis the studies of Cardoso et al. [3], Steward
et al. [30] and Tarantini et al. [40] were excluded from the analysis.
According to the results, the heterogeneity seems to be exactly the same
(I2=75%) and the relative risk is slightly lower (RR=1.66VSRR=1.70).the outcome mortality.
emia as independent predictor of mortality.
Table 3
Summary of the meta-analysis test.
Factor of
comparison
Studies
included
Participants Statistical Method in
random-Effect Model
Effect size
(95% CI)
Test for overall effect
(p-value)
Test of heterogeneity
(p-value)
Age 13 15,407 MD 3.40 [2.33, 4.47] b0.00001 b0.00001
Gender/males 16 14,296 RR 1.00 [0.94, 1.06] 1.00 b0.00001
Gender/females 16 14,296 RR 0.97 [0.85, 1.11] 0.67 b0.00001
Mortality 16 9251 RR 1.70 [1.47, 1.98] b0.00001 b0.00001
Readmission 5 2217 RR 1.57[1.17–210] 0.003 0.005
LOS 4 2117 RR 1.25 [0.59–1.90] 0.0002 0.48
NYHA class I&II 4 5027 RR 0.71 [0.55, 0.90] 0.005 0.09
NYHA class III &IV 8 13,426 RR 1.23 [0.99, 1.52] 0.06 0.005
Diabetes 13 16,011 RR 1.30 [1.18, 1.42] b0.00001 0.02
CRF 5 4242 RR 2.27 [2.05, 2.51] b0.00001 0.41
Hypertension 9 4307 RR 0.92 [0.74, 1.15] 0.48 b0.00001
COPD 5 8605 RR 0.99 [0.90, 1.08] 0.76 0.82
AF 8 5097 RR 0.97 [0.81, 1.17] 0.78 0.003
Hb level g/dl 9 12,548 MD −2.98 [−3.24,−2.72] b0.00001 b0.00001
Creatinine level 9 5608 MD 0.35 [0.09, 0.61] 0.007 b0.00001
SBP mm/Hg 7 13,682 MD −4.39 [−6.40,−2.38] b0.00001 0.002
DBP mm/Hg 6 9538 MD −5.67 [−7.19,−4.15] b0.00001 0.001
Ischemic etiology of HF 11 14,702 RR 1.23 [1.12, 1.36] b0.0001 0.0005
Valve etiology of HF 6 2136 RR 1.27 [0.98, 1.64] 0.07 0.24
Smoking 7 16,563 RR 0.76 [0.57, 1.00] 0.0009 b0.00001
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mortality, excluding the studies that had a RR N 2.5 in the ﬁrst analysis.
In order to conduct the analysis four studies excluded from the test:
Elabbasi et al., Lupon et al., Shamagian et al., Tarantini et al. According
to the test the RR or death remain statistically signiﬁcant RR = 1.50
and simultaneously the heterogeneity seems to be lower I2 = 61%.
Lastly, we tried to perform an adjusted analysis for anemia as inde-
pendent predictor of mortality using the results from Cox proportional
hazards regression model or a logistic regression model of the studies.
Only seven studies have been found to present the results from the
multivariate analysis and also in the same effect measure and in this
case hazard ratio. All of the studies were adjusted for gender and age.
Other covariates were adjusted for: NYHA class, diabetes, CRF, obesity,
COPD, sodium, creatinine, race, reason of admission, LOS, ischemic
heart disease, blood pressure (BP), heart rate, glomerular ﬁltration
rate, atrial ﬁbrillation, hypertension, vascular disease and Ejection
fraction.
Speciﬁcally, the above factors were tested in studies as follow:
NYHA class: Elabbasi et al. [23], Ferreira et al. [35] andWaldum et al.
[31].
Diabetes: Elabbasi et al. [23], Teng et al. [41], Torrijos et al. [34] and
Waldum et al. [31].
CRF: Elabbasi et al. [23] and Teng et al. [41].
Obesity: Elabbasi et al. [23].
COPD: Elabbasi et al. [23].
Sodium: Elabbasi et al. [23] and Waldum et al. [31].
Creatinine: Elabbasi et al. [23], Ferreira et al. [35], Teng et al., Torrijos
et al. [34] and Von Haehling et al. [13].
Race: Nathavitharana et al. [39].
Reason of admission: Nathavitharana et al. [39].
LOS: Teng et al. [41] and Von Haehling et al. [13].
Ischemic heart disease: Teng et al. [41] and Waldum et al. [31].
Blood pressure (BP): Teng et al. [41], Von Haehling et al. [13] and
Waldum et al. [31].
Heart rate: Teng et al. [41].
Glomerular ﬁltration rate: Teng et al. [41] and Waldum et al. [31].
Atrial ﬁbrillation: Torrijos et al. [34].
Hypertension: Torrijos et al. [34].
Vascular disease: Waldum et al. [31].
Ejection fraction: Von Haehling et al. [13] and Waldum et al. [31].The main outcomes are summarized in the Table 3.
4. Discussion
The currentmeta-analysis enables us to update the existing informa-
tion about HF and anemia and also illustrates the proﬁle of the patients
suffering from the co-morbidity. From the search in the three databases:
PubMed, Cochrane Library and CINAHL we found twenty-six studies to
meet the inclusion criteria.
Using the software program Review Manager 5.3 of Cochrane
Library, we conducted ameta-analysis based on the results of the actual
studies. Several trials over time, tried to estimate the prevalence of
anemia. Each time the author came up with different values with a
narrower or wider interval ﬂuctuation. According to the included
studies in the present report, the prevalence of anemia ranges from
14% -71%.
The broad and different values of anemia prevalence could be easily
explained for the absent of a universal deﬁnition. Another explanation
is the duration of follow-up in each study and the difference among
patients' characteristics.
In all of the studies, except the studies of Torrijos et al. [34] and
Bermejo et al. [27] the research team used baseline Hb level. In the
study of Torrijos et al. [34], they used Hb levels at discharge supporting
that this is a more reliable indicator.
4.1. Understanding the basics
Over the last decade, researcher's tried to clarify which factor is the
cause and which is the effect. Both anemia and HF are complicated
and are even more when they co-exist. Cardoso et al. [3] found that
the frequency of anemia between hospitalized patients with more
critical medical condition is consistent that anemia is a marker of a
serious disease. The pathophysiological mechanisms underlying the
worsening of prognosis in patients with HF and anemia are not yet
fully understood. Diminished peripheral vascular resistant due to
lower blood pressure and simultaneously stimulates the sympathetic
nervous system as well as the rennin-angiotensin- aldosterone system.
Since the renin- angiotensin-aldosterone system activated, this pro-
motes retention of sodium and water. Thus, there is an increase in car-
diac output and the same time greater the cardiac work [6,44–45]. The
ﬁndings from Anand et al. [16] support the above statement, arguing
that for every 1 g/dl increase in hemoglobin equals to 4,1 g/m2 reduction
in left vertical mass index within six months.
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Using the data from the twenty-seven quantitative studies, we came
upwith updated information of the last decade for the co-morbidity HF-
anemia. Generally, our ﬁndings are in the same line with previous
studies. The mortality rate as the rehospitalization seems to be higher
in patients with anemia. Patients with anemia which have a higher
relative risk of 1.74 and 1.57 in experiencing death or re-admission
episodes, respectively compared to patientswithout anemia. The results
are similar to the conclusions of other studies. In a study of 1130
patients, Mozaffarian et al. [46] found that 1% decrease in hematocrit
is associated with 3% increase in the risk of death. Likewise, Teng et al.
[41] supports that for every 1 g/dl increase in hemoglobin levels, equals
to 7% decline in mortality events. As for the re-admission, Felker et al.
[15] reported that every 1 g/dl reduction in hemoglobin estimates
a 12% increase in risk of death or re-hospitalization within 60 days.
Unfortunately, the data we extracted does not allow an estimation in
which stage of anemia (Hb level) the risk of mortality or morbidity is
increased. Thus, testing the risk of mortality based in Hb levels, we can
extract the conclusion that the severe the anemia, the poorer the prog-
nosis. Our conclusion is consistent with published studies. More specif-
ically, Young et al. [29] refers that in-patients hospitalized with HF,
anemia is associated with serious outcomes. Patients with Hb lower
than 10 g/dl, is more likely to experience a mortality or re-admission
event and also stay longer in hospital.
It is important to highlight that in our knowledge, this is the ﬁrst
time data were used in a meta-analysis for the length of hospital stay
for patients with anemia and HF. According to the test, patients with
anemia are hospitalized for more days in comparison to patients with
heart failure who do not have anemia. A signiﬁcant statistical value
was founded for this test but we consider further investigation, as the
result came up from only four studies.
At the end, patients with heart failure seem to be in worsened
functionality based on NYHA classiﬁcation, for this fact it is not clear if
anemia impairs the functionality or patients with more severe heart
failure, tending to exhibit anemia. Steward et al. refers, that it remains
uncertain if anemia causes severe heart failure or if it is just a marker
of a higher risk.4.3. Outline of patient's proﬁle
Based on our results, males and females have the same chance to
experience the co-morbidity, but the same does not apply for the age.
Patients with anemia tend to be older maybe because age causes a pro-
gressive depression of hematopoiesis. Several studies have examined
the factor age separating the following two groups, 65 years and youn-
ger patients. The former according to Nathavitharana et al. [39] have
approximately twice prevalence to have anemia.
Another major issue is the possible co-morbidities that patients'
with HF may have in combination with anemia. Generally, for all four
co-morbidities that we tested we found a greater correlation with the
patient's group who had anemia. This result can easily justify the fact
that patients who are experiencing anemia tend to be more severely
ill as referred above. To support our statement, we can report the con-
clusion of Felker et al. [15] who found that lower Hb was associated
with greater co-morbidity, the larger portion of the share has the
renal failure. There is a pathophysiological mechanism as an explana-
tion of the co-existence of these two situations. Renal dysfunction can
lead to the decreased production of endogenous erythroprotein that
might ultimately induce anemia. As a result, cardiac hemodynamic
load increases and that is what is called the cardio-renal syndrome.
According to this mechanism, we could also explain our ﬁndings for
both systolic and diastolic blood pressure. Lastly, according to the
above explanation for renal dysfunction, we could base our result for
the higher creatinine in patients with anemia.From this systematic review and meta-analysis we tried to identify
the proﬁle and prognosis of patients with HF and anemia, simulta-
neously updating the existence of information on this topic. Generally
based on our ﬁndings, patients with HF have poorer prognosis when
anemia co-exists. Studies examining possible therapies and the effec-
tiveness of medications were excluded from this report, although we
recognized the importance of these factors. Nevertheless, the prognosis
of patients with HF and anemia remains poor.
5. Conclusions
The present meta-analysis gives an outline proﬁle of patients with
the co-morbidity HF and anemia. The aim of the project was to examine
patient's prognosis in terms of clinical outcomes. The updated informa-
tion from the current meta-analysis supports the ﬁndings of previous
meta-analysis of worsened prognosis in patients with HF. Furthermore,
according to our ﬁndings the severity of anemia is an important predic-
tor of morbidity and mortality events. Unfortunately, the available data
did not allow us to extract the conclusion inwhich stage (Hb level) ane-
mia becomes a negative predictor of patient's prognosis. Greater studies
are needed to be examined.
6. Limitations
The current systematic review andmeta-analysis has several limita-
tions. Firstly, the research on the databases had been undertaken only
by one reviewer. Secondly, it only included studies published in English,
therefore, we did not consider studies published in other languages
other than English or unpublished studies which could lead to different
results.
Furthermore, the present search strategy may have failed to identify
some important studies.
Lastly, we consider the statistical heterogeneity that we foundwhen
poolingwas completed to extract results for some testing factors. Possi-
ble explanations for heterogeneity, is the variance deﬁnitions of anemia,
the duration of follow up and the between studies differences in local
practice and the year that each study was conducted. Using random
effects model, we tried to incorporate heterogeneity between studies.
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